Citigroup Inc. Decreases Stock Holdings in Collegium Pharmaceutical, Inc. $COLL

Citigroup Inc. trimmed its holdings in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 97.5% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 86,589 shares of the specialty pharmaceutical company’s stock after selling 3,411,208 shares during the period. Citigroup Inc. owned 0.27% of Collegium Pharmaceutical worth $3,030,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also modified their holdings of the stock. Federated Hermes Inc. raised its stake in Collegium Pharmaceutical by 67.0% during the 3rd quarter. Federated Hermes Inc. now owns 872 shares of the specialty pharmaceutical company’s stock worth $31,000 after acquiring an additional 350 shares in the last quarter. CWM LLC grew its holdings in shares of Collegium Pharmaceutical by 453.9% during the second quarter. CWM LLC now owns 1,407 shares of the specialty pharmaceutical company’s stock worth $42,000 after purchasing an additional 1,153 shares during the last quarter. Hantz Financial Services Inc. increased its position in shares of Collegium Pharmaceutical by 137.7% during the third quarter. Hantz Financial Services Inc. now owns 1,714 shares of the specialty pharmaceutical company’s stock worth $60,000 after purchasing an additional 993 shares in the last quarter. EverSource Wealth Advisors LLC lifted its holdings in shares of Collegium Pharmaceutical by 744.9% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,484 shares of the specialty pharmaceutical company’s stock valued at $73,000 after purchasing an additional 2,190 shares during the last quarter. Finally, NewEdge Advisors LLC boosted its position in shares of Collegium Pharmaceutical by 304.6% in the 2nd quarter. NewEdge Advisors LLC now owns 3,047 shares of the specialty pharmaceutical company’s stock valued at $90,000 after purchasing an additional 2,294 shares during the period.

Collegium Pharmaceutical Stock Down 5.9%

COLL stock opened at $37.28 on Friday. The stock has a market capitalization of $1.18 billion, a PE ratio of 21.80 and a beta of 0.67. The company has a fifty day moving average of $45.74 and a 200-day moving average of $42.09. The company has a debt-to-equity ratio of 2.59, a quick ratio of 1.48 and a current ratio of 1.57. Collegium Pharmaceutical, Inc. has a one year low of $23.23 and a one year high of $50.79.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its quarterly earnings results on Thursday, February 26th. The specialty pharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.20 by ($0.16). Collegium Pharmaceutical had a return on equity of 98.65% and a net margin of 8.05%.The firm had revenue of $205.45 million for the quarter, compared to analysts’ expectations of $206.36 million. During the same period in the prior year, the company earned $1.77 earnings per share. The company’s revenue for the quarter was up 12.9% on a year-over-year basis. As a group, analysts expect that Collegium Pharmaceutical, Inc. will post 5.62 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms have commented on COLL. Zacks Research lowered Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 6th. HC Wainwright reaffirmed a “buy” rating and issued a $60.00 target price (up from $46.00) on shares of Collegium Pharmaceutical in a report on Friday, January 9th. Needham & Company LLC reduced their price target on shares of Collegium Pharmaceutical from $56.00 to $54.00 and set a “buy” rating for the company in a research report on Thursday, February 26th. Barclays decreased their price target on shares of Collegium Pharmaceutical from $58.00 to $56.00 and set an “overweight” rating for the company in a research note on Friday, January 9th. Finally, Truist Financial set a $58.00 price objective on shares of Collegium Pharmaceutical in a research note on Tuesday, February 10th. Five investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $53.00.

Insider Buying and Selling at Collegium Pharmaceutical

In related news, EVP Scott Dreyer sold 49,976 shares of the company’s stock in a transaction on Tuesday, March 3rd. The stock was sold at an average price of $40.41, for a total transaction of $2,019,530.16. Following the transaction, the executive vice president owned 71,770 shares of the company’s stock, valued at $2,900,225.70. This represents a 41.05% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 2.51% of the stock is currently owned by company insiders.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.